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ABCB4 flops phosphatidylcholine into the bile canaliculus to protect the biliary tree 
from the detergent activity of bile salts. Homozygous-null ABCB4 mutations cause 
the childhood liver disease, progressive familial intrahepatic cholestasis, but cause 
and effect is less clear with many missense mutations linked to less severe 
cholestatic diseases. ABCB4S320F, in particular, is described in 13 patients, including 
in heterozygosity with ABCB4A286V, ABCB4A953D and null mutants, whose symptoms 
cover the spectrum of cholestatic disease. We sought to define the impact of these 
mutations on the floppase, explain the link with multiple conditions at the molecular 
level, and investigate potential for reversal. ABCB4S320F, ABCB4A286V and 
ABCB4A953D expression was engineered in naïve cultured cells. Floppase 
expression, localisation and activity were measured by western blot, confocal 
microscopy and lipid transport assays, respectively. ABCB4S320F was fully-active for 
floppase activity but expression at the plasma membrane was reduced to 50%. 
ABCB4A286V expressed and trafficked efficiently but could not flop lipid, and 
ABCB4A953D expressed poorly and was impaired in floppase activity. Proteasome 
inhibition stabilised nascent ABCB4S320F and ABCB4A953D but did not improve plasma 
membrane localisation. Cyclosporin-A improved plasma membrane localisation of 
both ABCB4S320F and ABCB4A953D, but inhibited floppase activity. Conclusions: The 
level of ABCB4 functionality correlates with, and is the primary determinant of, 
cholestatic disease severity in these patients. ABCB4S320F homozygosity, with half 
the normal level of ABCB4, is the tipping point between more benign and potentially 
fatal cholestasis and makes these patients more acutely sensitive to environmental 
effects. Cyclosporin-A increased expression of ABCB4S320F and ABCB4A953D 
suggesting that chemical chaperones could be exploited for therapeutic benefit to 
usher in a new era of personalised medicine for patients with ABCB4-dependent 
cholestatic disease. 
  




Bile flow across the canalicular membrane of hepatocytes is dependent on three 
primary-active transport proteins, the ATP binding cassette (ABC) transporters 
ABCB11(1, 2) and ABCB4(3) and the P-type ATPase ATP8B1(4) (formerly known as 
BSEP, MDR3, and FIC1, respectively). The emerging picture is that ABCB4 and 
ATP8B1 (which functions in complex with its accessory protein CDC50) function to 
protect the hepatocyte (and cholangiocytes that line the bile ducts) from the 
deleterious detergent activity of bile salts(5). ABCB4 is thought to flop the membrane 
lipid phosphatidylcholine (PC) from the inner to the outer leaflet of the canalicular 
membrane(3, 6, 7), from where it is extracted into the canaliculus by bile salts 
transported by ABCB11 to form mixed micelles. This reduces the detergent activity 
of the bile salts(3, 8). In contrast, ATP8B1/CDC50 flips the aminophospholipids, 
phosphatidylserine, and phosphatidylethanolamine from the outer to the inner leaflet 
of the membrane(9). This activity is thought to maintain lipid asymmetry of the 
canalicular membranes of hepatocytes and cholangiocytes, to resist the detergent 
activity of bile salts(5, 10). All three transporters are known to be critical for bile flow 
because null mutations in ATP8B1, ABCB11 and ABCB4 cause progressive familial 
intrahepatic cholestasis (PFIC) types 1, 2 and 3, respectively. These monogenetic, 
autosomal recessive, diseases are characterised by intrahepatic cholestasis within 
the first year of life which leads to severe growth retardation. Progression to liver 
failure typically occurs within the first two decades and is often only treatable by 
orthotopic liver transplantation(7). 
 
Dysfunction of each of the transporters is also considered causative in less severe 
but nevertheless debilitating complex liver disorders. Of relevance to the current 
study, ABCB4 SNPs have been linked to drug-induced cholestasis (DIC(11)), 
intrahepatic cholestasis of pregnancy (ICP(12)) and low phospholipid-associated 
cholelithiasis (LPAC(13)).  Recently, ABCB4 SNPs have also been suggested to 
predispose to cholangiocarcinoma(14). In the rare type-3 PFIC the link between 
mutation and disease is clear, but the majority of cholestatic liver diseases are 
complex conditions and a causative link with ABCB4 SNPs that are typically private 
to individual families is suspected but not proved, with critical evidence at the 
functional and mechanistic level of protein expression and floppase activity lacking.  
 




Biochemical characterisation of the effect of ABCB4 SNPs directly has, hitherto, 
been challenging for several reasons: it is technically difficult to measure 
translocation of PC from the inner to the outer leaflet of the plasma membrane (this 
has been achieved previously but interpretation is complicated by the use of 
fluorescently-tagged PC analogues (6, 15)), and expression of functional PC 
floppase, transiently in vitro, is deleterious to cultured cells(5). Some insight has 
been obtained by mimicking mutations in the multidrug resistance transporter 
ABCB1, the closest homologue of ABCB4(16, 17). However, this approach is only 
relevant if the particular amino acid is conserved in both proteins and performs the 
same function, ruling out the study of mutations that directly influence PC binding, or 
responses to hormones of pregnancy, contraceptives and other drugs. Recently, we 
described the transient expression of active ABCB4 in naïve HEK293T cells by co-
expressing it with ATP8B1/CDC50 to maintain the integrity of the plasma 
membrane(5). This ameliorates the cytotoxic effect of ABCB4 function. We now 
report the use of this expression system to characterise variant ABCB4 and describe 
the relationship between genotype and phenotype in a cohort of non-familial patients 
who share the S320F mutation and who presented with a spectrum of hepatobiliary 
disease (Table 1). 
 
In the current study, we focus on ABCB4S320F and other mutations (ABCB4A286V and 
ABCB4A953D) that are found in heterozygosity with ABCB4S320F, and characterised 
their impact on protein expression, plasma membrane localisation and floppase 
function. The S320F variant is particularly interesting because it is described in 
thirteen case studies and is linked with the development of cholestatic disorders 
which unusually cover the whole spectrum of severity including several ICP, LPAC 
DIC and PFIC3 cases. The distinct in vitro phenotypes correlate with the severity of 
disease confirming that ABCB4 genotype is the primary determinant of cholestatic 
pathophysiology. The phenotypes of ABCB4S320F and ABCB4A953D, but not 










Plasmids pcDNA3-ABCB4, pcDNA3-ABCB4 E558Q, pCIneo-ATP8B1, and pCIneo-
CDC50 were described previously(5). Site-directed mutagenesis to introduce the 
SNPs c.857C>T (p.A286V), c.959C>T (p.S320F) and c.2858C>A (p.A953D) into the 
wild-type ABCB4 cDNA(18) was performed using QuickChange-II (Stratagene, La 
Jolla, California). Mutagenesis was verified by sequencing of the entire cDNA and 
promoter region. 
Mutagenic Oligonucleotides (5’ – 3’):  
A286V, GAAAGGTATCAGAAACATTTAGAAAATGTCAAAGAGATTGGAATTAAAAAAGCTATT;  
S320F, CTGGCCTTCTGGTATGGATTCACTCTAGTCATATCAAA;  
A953D, GCATTTATGTATTTTTCCTATGACGGTTGTTTTCGATTTGGTGCA. 
 
Mammalian Cell Culture 
 
Human embryonic kidney (HEK293T) cells were cultured and transiently transfected 
as described previously(5). Cells were seeded 24h prior to transfection at a density 
of 4.6 x 104 / cm2 and triple-transfected with 2.5µg each of ABCB4, ATP8B1 and 
CDC50 using polyethyleneimine (Sigma, Gillingham UK). Where ATP8B1 and 
CDC50 were omitted, DNA concentration was maintained constant with 5µg of 
empty pCIneo. Where applied, MG132 or cyclosporin A (CsA) solubilised in 
dimethylsulphoxide (DMSO) was added 24h post-transfection. ABCB4 localisation 




Cells were washed twice with PBS and harvested in 150mM NaCl, 20mM HEPES 
pH 7.4, 1% SDS, 1× EDTA-free complete protease inhibitor cocktail from Roche, 
1mM PMSF. Crude protein lysates (1µg) were denatured in Laemmli sample buffer 
(70°C for 5 min), separated by SDS-PAGE, and transferred to polyvinylidene 
difluoride membrane (Millipore, Billerica Massachusetts). Blots were probed with 
mouse anti-ABCB4 monoclonal P3II-26 (Sigma, Gillingham UK), diluted 1:2,000 and 
mouse anti-β-tubulin (SourceBioscience, Nottingham UK) diluted 1:2,000. Primary 
antibodies were detected using goat anti-mouse secondary antibody, conjugated to 
horseradish peroxidase diluted 1:2,000 (Santa Cruz, Dallas Texas) and visualised by 




enhanced chemiluminescence (GE Healthcare, Amersham UK), or goat anti-mouse, 
conjugated to IRDye 680 diluted 1:20,000 (LI-COR, Lincoln Nebraska), for 
visualisation by the Odyssey scanning system. ABCB4 abundance normalised 




Cells were seeded onto 12mm glass coverslips coated with poly-L-lysine, 24h prior 
to triple-transfection. Cells were fixed 48h post-transfection in ice-cold 10% acetone 
(in ethanol) for 20min, blocked in 1% BSA (in PBS) for 1h, and incubated with 
primary antibodies, mouse anti-ABCB4 (P3II-26; Sigma, Gillingham UK), and rabbit 
anti-Na+/K+ ATPase (H-300; Santa Cruz, Dallas Texas) at 1:50 dilution in PBS + 1% 
BSA for 1h. The cells were washed 3x in PBS and incubated with secondary 
antibody (goat anti-mouse Alexa568 or goat anti-rabbit Alexa488; Invitrogen, Paisley 
UK), diluted 1:500 in PBS + 1% BSA for 1h. The labelled cells were washed 3x in 
PBS, mounted on glass slides and imaged using a ZEISS 710 confocal microscope. 
Images were obtained using a plan-apochromat 63× oil immersion objective with a 
numerical aperture of 1.4.  
 
Phosphatidylcholine Efflux Assay 
 
PC extraction was measured as described previously(5). Briefly, cells were triple-
transfected in poly-L-lysine coated 6-well dishes and fed 2µCi (~24pmol) 3H-choline 
chloride (PerkinElmer, Waltham Massachusetts) 24h post-transfection. The cells 
were washed 24h later in pre-warmed DMEM and incubated with 2mM sodium 
taurocholate hydrate (TC) in DMEM. Media was recovered and cellular lysates 
prepared. Radionuclide content was measured by liquid scintillation. PC extraction is 
calculated as radionuclide detected in the media as a percentage of the total (media 
plus lysate). The data were normalised against PC extraction from cells expressing 
the non-functional E558Q Walker B mutant of ABCB4. 
 
Results 





Expression levels of Variant ABCB4 
 
Mutations were introduced into the ABCB4 cDNA to mimic the SNPs observed in 
patients and to encode the A286V, S320F and A953D variant proteins. HEK293T 
cells were transiently-transfected with either a single plasmid encoding an ABCB4-
variant or three plasmids encoding the ABCB4-variant plus ATP8B1 and CDC50 (the 
pCIneo-ABCB4 plasmids were kept constant at 2.5µg throughout). The transfection 
conditions were optimised to achieve a confluent monolayer of cells 48hrs post-
transfection. Sixty percent of the cells in the population were transfected and 98% of 
the transfected cells took up all three plasmids (supplementary figure 1). Expression 
of each variant protein was compared to wild-type ABCB4 and a non-functional 
mutant carrying a point mutation in the Walker B motif of the first nucleotide-binding 
domain, ABCB4E558Q (Figure 1). The wild-type transporter expressed poorly in single-
transfected cells likely due to the deleterious effect of flopping excess PC into the 
outer leaflet of the plasma membrane, but expressed well when triple-transfected 
with ATP8B1/CDC50(5). In contrast, the non-functional Walker B mutant ABCB4E558Q 
expressed equally well under both conditions. The three variants had distinct 
expression profiles. ABCB4A286V was similar to the Walker B mutant and expressed 
to high levels in both the single and triple-transfected cells. ABCB4A953D expressed 
poorly in both conditions and to only 16.3% of the wild-type level in the triple-
transfected cells. ABCB4S320F also expressed to similar levels in the single- and 
triple-transfected cells, but to 50.1% of the level achieved by the wild-type 
transporter in the triple-transfected cells.  
 
ABCB4S320F and ABCB4A286V Traffic to the Plasma Membrane while 
ABCB4A953D is Largely Retained Intracellularly  
 
Triple-transfected cells were fixed, stained and analysed by confocal microscopy to 
determine whether the variant proteins could traffic to the plasma membrane (Figure 
2). Wild-type ABCB4 traffics efficiently to reside in the plasma membrane as shown 
by the substantial co-localisation with the Na+/K+-ATPase. Significant levels of 
ABCB4A286V and ABCB4S320F were also detected in the plasma membrane. 




ABCB4A953D, despite low level of expression, was also detected, but predominantly in 
the intracellular compartment with only a small fraction at the plasma membrane. 
This is consistent with the low level of expression of the mature form of ABCB4A953D 
observed by western analysis. 
 
ABCB4S320F is Fully Active, ABCB4A953D is Partially Active and 
ABCB4A286V is Inactive for the Efflux of PC 
 
Triple-transfected cells were fed radiolabelled choline to convert into 3H-PC(19). The 
cells were incubated with taurocholate to extract the flopped PC from the outer 
leaflet of the plasma membrane. More 3H-PC is extracted from cells that express 
wild-type ABCB4 than those that express the catalytically inactive ABCB4E558Q 
(Figure 3). 3H-PC extracted from cells expressing ABCB4S320F was reduced to 49% 
that of cells expressing wild-type ABCB4, while the level mediated by cells 
expressing ABCB4A286V or ABCB4A953D was very low. After correction for ABCB4 
expression level (Figure 3, inset) the data indicate that ABCB4S320F is fully active as 
a floppase, while ABCB4A286V is unable to flop PC. ABCB4A953D retains partial 
functionality with a floppase activity 29.4% that of the wild-type level after correction 
for the low level of mature protein expressed.  
 
Proteasome Inhibition Causes Accumulation of Immature ABCB4S320F 
and ABCB4A953D but does not Improve Trafficking to the Plasma 
Membrane 
 
Membrane proteins that fold inefficiently are targeted for degradation by the 
proteasome via the endoplasmic reticulum-associated degradation (ERAD) 
pathway(20, 21). Inhibition of the proteasome could therefore, potentially, slow the 
rate of degradation and allow the variant proteins to adopt the appropriate fold. As a 
test of this hypothesis, triple-transfected cells expressing either wild-type ABCB4, 
ABCB4S320F or ABCB4A953D were treated with the proteasome inhibitor MG132 
(10µM) from 24h post-transfection. Western analysis showed that these cells 
accumulated a smaller molecular weight species of ABCB4 (Figure 4A). This species 
is not glycosylated and migrates with the same electrophoretic mobility as 




deglycosylated ABCB4 (Figure 4B), therefore most likely represents full length, 
immature protein which accumulates in the ER (Figure 5A, 5B and 5C). Inhibition of 
the proteasome appears to have little impact on maturation of ABCB4 because there 
is no increase in abundance of the mature, fully glycosylated protein. These data 
indicate that ABCB4S320F, ABCB4A953D and also wild-type ABCB4 are subject to 
ERAD but that inhibition of the proteasome, by itself, does not improve abundance at 
the plasma membrane in vitro and is not likely to improve ABCB4 density in the 
canalicular membrane of patients. 
 
Cyclosporin-A Improves Folding of ABCB4 but Inhibits PC Efflux 
 
CsA can improve the folding kinetics of the drug efflux pump ABCB1(22). Incubation 
of triple-transfected cells with CsA 24h post-transfection caused a marked increase 
in the expression of ABCB4S320F and also wild-type ABCB4 (Figure 4C). Even at low 
micromolar concentrations of CsA, ABCB4S320F can attain the expression level 
observed for the wild-type protein in untreated cells. In cells expressing wild-type 
ABCB4 and ABCB4S320F the improved level of protein expression resulted in 
increased localisation at the plasma membrane (Figure 5A and 5B, lower panels). 
The expression level of ABCB4A953D was not increased by CsA (Figure 4C), but the 
treatment did improve localisation of this variant to the plasma membrane (Figure 
5C). Unfortunately, CsA treatment from 24h post-transfection was found to inhibit 
ABCB4 PC floppase activity (Figure 4D). This was apparent even if the treated cells 
were washed extensively 48hrs post-transfection and CsA was omitted from the 




We describe the characterisation of three missense variants of ABCB4 that are 
linked to a spectrum of cholestatic liver disease in fourteen case studies. The 
variants were expressed in HEK293T cells which do not polarise but offer two key 
advantages: they do not express endogenous ABCB4 and they are highly 
transfectable which is necessary for efficient triple-transfection with ATP8B1/CDC50 
to avoid negative selective pressure acting on PC floppase activity. Taurocholate 




was added to the cells to extract the 3H-PC flopped by ABCB4 (we showed 
previously that there is no cellular efflux in the absence of an extracellular acceptor 
(5)). ABCB4A286V expressed and localised efficiently to the plasma membrane in vitro 
but could not efflux PC. Expression of ABCB4S320F and ABCB4A953D was reduced to 
50.1% and 16.3% of the wild-type floppase, respectively, and while ABCB4S320F 
trafficked to the plasma membrane, a large fraction of ABCB4A953D was retained 
intracellularly. Efflux of PC from cells expressing ABCB4S320F and ABCB4A953D 
(respectively, 49% and 5% of the level from cells expressing wild-type ABCB4), 
which when corrected for floppase abundance at the plasma membrane indicates 
that ABCB4S320F is fully functional while ABCB4A953D retains only 29.4% floppase 
activity. The lower density of this functional of ABCB4S320F in the plasma membrane, 
and its insensitivity to the ATP8B1/CDC50 status of the cells suggests that HEK293T 
cells have a threshold level of PC floppase activity that they can tolerate. This is not 
surprising because the lipids of all cells are asymmetrically arranged in the plasma 
membrane and therefore all cells are likely to have flippases and floppases for 
specific lipids to maintain asymmetry. We expect that this homeostatic mechanism is 
capable of withstanding the imbalance caused by ABCB4S320F expression. The in 
vitro data appear consistent with the available expression and immunohistochemistry 
data from clinical samples (albeit from chronically diseased liver). Patient 5 (Table 1), 
who is homozygous for ABCB4S320F is reported to express 50% of the normal level of 
ABCB4(23), and patient 14 who is homozygous for ABCB4A953D shows a marked 
reduction in expression (although this was not quantified by the authors(24)). This 
indicates that our in vitro system is a good model of the in vivo situation and can be 
used to characterise the impact of missense SNPs on ABCB4 protein expression, 
localisation and function. 
 
The in vitro phenotype of the variant floppases correlates with the severity of disease 
confirming that ABCB4 genotype is the primary determinant of cholestatic 
pathophysiology in this cohort. The ABCB4S320F variant is common to the first 
thirteen patients described in Table 1. In patients 1 and 2(25), ABCB4S320F is 
heterozygous with either ABCB4Y279X (which, truncated to only a quarter of the 
polypeptide, would be unable to form a functional ABC transporter(26)) or the non-
active ABCB4A286V, and therefore ABCB4S320F would be the only functional ABCB4 
PC floppase present in the canalicular membrane. Extrapolating from the in vitro 




data indicates that less than one quarter of the normal activity of the PC floppase is 
unable to prevent damage to canalicular membranes and results in the severe 
childhood disease PFIC3. The critical effect of the level of ABCB4 expression and 
function is also supported by the two siblings described by Poupon et al.,(27) 
(patients 3 and 4; Table 1), who are heterozygous for ABCB4S320F and ABCB4A953D 
and so are likely to have only 27% of the PC floppase activity of a normal individual. 
These patients presented with LPAC characterised by cholesterol gallstones which 
precipitate from the bile due to the low solubility of cholesterol in mixed micelles that 
are low in PC(13). Unusually for LPAC patients, they developed PFIC3 in the third 
decade of life, suggesting that even a small increase in PC-floppase activity 
(compared to patients 1 and 2) can delay the onset of this progressive disease.  
 
In cases 10 – 13 (Table 1), ABCB4S320F is heterozygous with the wild-type allele and 
these patients present with LPAC, DIC or ICP(28-30). In DIC and ICP, the 
cholestasis is induced and limited by drugs (the contraceptive pill and fertility 
treatment in the two cases described) or pregnancy hormones which are thought to 
inhibit the transporters at the canalicular membrane directly(31) and/or reduce their 
levels of expression by direct inhibition of the farnesoid-X receptor(32). The allelic 
combination of patients 10 to 13 (where ABCB4S320F is combined with the wild-type 
allele) is likely to encode three quarters of the normal level of ABCB4 floppase 
activity, which we would argue is sufficient to protect against childhood PFIC3 but 
insufficient to prevent LPAC, DIC or ICP. It has been suggested previously that 
relation of genotype to phenotype in patients 11 to 13 may be complicated by 
additional variation at the ABCB11 locus. The ABCB11V444A variant is reported to 
express poorly compared to the wild-type allele both in vitro and in vivo(30, 33) and 
is likely, therefore, to reduce bile salt efflux across the canalicular membrane. 
Population studies have identified ABCB11V444A as a risk factor for several forms of 
cholestasis(30, 34-37). However, reduced bile salt efflux would be likely to reduce 
the toxicity of the bile in the canaliculae and therefore may be expected to alleviate 
the pathology of disease in patients with low levels of ABCB4. Patient 11 is 
homozygous for the wild-type ABCB11 allele, patient 12 is heterozygous and patient 
13 is homozygous for ABCB11V444A, but all present with biliary conditions of similar 
severity suggesting that the ABCB11 genotype is of little relevance in these cases.   
 




The tipping point for development of PFIC3 in childhood, would appear to be half the 
normal level of functional ABCB4. Patients 5 to 9 are homozygous for ABCB4S320F 
and so would be expected to express half the normal level of ABCB4. These patients 
presented with the full spectrum of cholestatic disease, including LPAC (patient 
6)(38), ICP (patients 7 and 9)(13, 39), DIC and ICP (patient 8)(13), and one patient 
(patient 5)(23) who presented with PFIC3 aged 8. Patient 5 responded to treatment 
with the less toxic bile acid, ursodeoxycholate, but developed liver fibrosis and 
gallstones by age 10. At the tipping point of ABCB4 functionality, these patients are 
likely to be more acutely sensitive to environmental affects such as therapeutic drug 
intake, hormones and diet which may modulate liver disease severity. A similar 
threshold effect has also been postulated for rodent models of ABCB4-dependent 
cholestatic disease(40). 
 
None of these SNPs are close to an exon/intron boundary and while an effect on 
message stability cannot be ruled out, the close correlation of the in vitro cell 
biological data with patient symptoms suggest that the phenotypic effects are 
mediated at the protein level. This implies that relatively subtle changes in ABCB4 
abundance and activity can affect bile composition and the progression of disease. 
The corollary, that relatively subtle improvement in PC flopping is likely to have 
significant therapeutic benefit, make ABCB4 an attractive target for intervention. The 
defects associated with ABCB4S320F and ABCB4A953D but not ABCB4A286V may be 
correctable by agents that improve ABCB4 protein level at the canalicular 
membrane. Treatment with CsA produced a marked improvement in abundance and 
plasma membrane localisation of both wild-type ABCB4 and ABCB4S320F, and also in 
the localisation of ABCB4A953D at the plasma membrane, but it was found to inhibit 
PC floppase activity. CsA is thought to act as a chemical chaperone for the drug 
efflux pump ABCB1 by binding directly to the nascent protein and improving folding 
kinetics by induced fit(22). The effects of CsA on the abundance, localisation and 
floppase activity suggests a similarly direct interaction with ABCB4. Despite the 
inhibitory effect, the CsA data provide proof-of-principle that the density of 
ABCB4S320F and ABCB4A953D at the plasma membrane can be manipulated, and that 
there is scope for development of drugs to target increased expression of the PC 
floppase at the canalicular membrane. 127 non-synonymous SNPs in ABCB4 have 
been identified to date (http://abcmutations.hegelab.org). In vitro characterisation will 




be key to stratify these missense variants of ABCB4 to clarify the relationship 
between genotype and phenotype, and to identify those disease-causing variants 
that could be targeted for therapeutic intervention.  
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  Sex Additional 
Mutations 
Disease Reference 
1 S320F Y279X   F NK PFIC3 Degiorgio et al., (25) 
2 S320F A286V   F NK LPAC to PFIC3 Degiorgio et al., (25) 
3
a
 S320F A953D   M ABCB11-V444A
+/-
  LPAC to PFIC3 Poupon et al., (27) 
4
a
 S320F A953D   F ABCB11-V444A
+/-
  LPAC to PFIC3 Poupon et al., (27) 
5 S320F S320F   M NK PFIC3 Colombo et al., (23) 
6 S320F S320F   NK NK LPAC Rosmorduc et al., (38) 
7 S320F S320F   F NK ICP Rosmorduc et al., (13) 
8 S320F S320F   F NK DIC
c
 and ICP Rosmorduc et al., (13) 
9 S320F S320F   F NK ICP Pauli-Magnus et al., (41)  
10 S320F WT   F NK ICP Bacq et al., (28) 
11
b
 S320F WT   F ABCB11-wt
+/+
  LPAC and ICP Zimmer et al., (29) 
12
b
 S320F WT   F ABCB11-V444A
+/- 
 LPAC Zimmer et al., (29) 




 and ICP Keitel et al., (30) 
14 A953D A953D   NK NK PFIC3 Keitel et al., (24) 
Table 1. Missense mutations in 14 patients with cholestatic liver disease who 
carry ABCB4S320F and related variants.  
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Patient 12 is nulligravid and also carries a SNP in the FXR gene which results 
in the missense mutation M1V and lowers the abundance of FXR by two 
thirds(42). The bile acid sensor FXR controls transcription of ABCB4 and 
ABCB11 therefore low levels of FXR in patient 12(29) is likely to lower ABCB4 
abundance further, but in parallel with ABCB11. a,bSiblings. cDrugs in these 
cases refer to prescription of the contraceptive pill or progesterone fertility 
treatment. NK: not known. 
 





Figure 1. Analysis of Expression of ABCB4 missense variants 
(A) Western blot of the expression of wild-type and variant ABCB4 in 
HEK293T cells in the absence and presence of ATP8B1/CDC50 as indicated 
(black vertical line indicates samples were run on the same gel but were non-
contiguous). The Walker B mutant E558Q was used as a control for 
expression of a non-functional protein. (B) Expression levels of the mature 
160kDa form of the ABCB4 variants in different biological replicates were 
normalised to wild-type ABCB4 expression expressed contemporaneously in 
the absence of ATP8B1/CDC50. Mean expression level +/- sem are plotted. 
Statistical analysis was by unpaired Student’s t-test (n ≥ 3; ***P < 0.005; ns, 
not significantly different). 
 
Figure 2. Trafficking of variant ABCB4 to the plasma membrane.  
Wild-type and variant ABCB4 were expressed in HEK293T cells in the 
presence of ATP8B1/CDC50. Cells were fixed, permeabilised and stained for 
ABCB4 (magenta) and the plasma membrane protein, Na+/K+-ATPase 
(green). Nuclei were stained with DAPI (blue) and the cells imaged by 
confocal microscopy. Scale bar denotes 20 µm 
 
Figure 3. Phosphatidylcholine efflux by ABCB4 variants in the presence of 
ATP8B1/CDC50. 
PC floppase activity was tested in HEK293T cells expressing wild-type 
ABCB4 (WT), ABCB4S320F, ABCB4A286V, or ABCB4A953D in the presence of 
ATP8B1/CDC50. 3H-PC extracted in the presence of 2mM TC was calculated 
as the percentage of total cellular radioactivity after subtraction of the 
background level from cells expressing the Walker B mutant ABCB4E558Q. The 
data were analysed by Student’s t-test (n ≥ 3; *P < 0.01, ***P < 0.005). Inset 
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shows percentage mean PC floppase activity after correction for ABCB4 
variant mean expression levels. 
 
Figure 4. Effects of Potential Modulators of ABCB4 expression and function 
(A) Cells were triple-transfected to express wild-type ABCB4 (WT), 
ABCB4S320F or ABCB4A953D. Treatment with the proteasome inhibitor MG132 
(10µM) 24h post-transfection induced accumulation of a smaller molecular 
weight form of the floppase, detected by western analysis. (B) Whole-cell 
lysates treated with PNGase F shows that deglycosylated mature protein 
migrates with the same mobility as the smaller molecular weight form 
produced by treatment with MG132 (loading was adjusted to ensure similar 
levels of variant and wild-type protein). (C) Representative gels and bar graph 
showing that treatment of triple transfected cells with CsA 24h post-
transfection reproducibly causes the mature wild-type ABCB4 and 
ABCB4S320F to accumulate, but has no effect on the abundance of 
ABCB4A953D. Expression levels of the mature protein are normalised against 
β-tubulin expression. (D) CsA inhibits the PC floppase activity of wild-type 
ABCB4. Triple-transfected cells were incubated with 0-1µM CsA 24h post-
transfection for the indicated times. The media was washed from the cells and 
replaced with fresh media containing TC. Data were analysed by Student’s t-
test (n ≥ 3; *P < 0.01, ***P < 0.005). Black vertical line(s) on panels B and C 
indicate that samples were run on the same gel but were non-contiguous. 
 
Figure 5. Effect of MG132 and CsA on ABCB4 Expression and Trafficking  
(A) Wild-type ABCB4. (B) ABCB4S320F. (C) ABCB4A953D. Cells were cultured 
on glass coverslips, triple-transfected and treated 24h post-transfection with 
the proteasome inhibitor MG132 (10µM) or the chemical chaperone CsA 
(1µM) as indicated. The cells were fixed, stained and imaged by confocal 
microscopy 48h post-transfection. Staining as per Figure 2. Scale bar, 20µm. 






Figure 1. Analysis of Expression of ABCB4 missense variants  
(A) Western blot of the expression of wild-type and variant ABCB4 in HEK293T cells in the absence and 
presence of ATP8B1/CDC50 as indicated (black vertical line indicates samples were run on the same gel but 
were non-contiguous). The Walker B mutant E558Q was used as a control for expression of a non-functional 
protein. (B) Expression levels of the mature 160kDa form of the ABCB4 variants in different biological 
replicates were normalised to wild-type ABCB4 expression expressed contemporaneously in the absence of 
ATP8B1/CDC50. Mean expression level +/- sem are plotted. Statistical analysis was by unpaired Student’s t-
test (n ≥ 3; ***P < 0.005; ns, not significantly different).  
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Figure 2. Trafficking of variant ABCB4 to the plasma membrane.  
Wild-type and variant ABCB4 were expressed in HEK293T cells in the presence of ATP8B1/CDC50. Cells were 
fixed, permeabilised and stained for ABCB4 (magenta) and the plasma membrane protein, Na+/K+-ATPase 
(green). Nuclei were stained with DAPI (blue) and the cells imaged by confocal microscopy. Scale bar 
denotes 20 µm.  
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Figure 3. Phosphatidylcholine efflux by ABCB4 variants in the presence of ATP8B1/CDC50.  
PC floppase activity was tested in HEK293T cells expressing wild-type ABCB4 (WT), ABCB4S320F, 
ABCB4A286V, or ABCB4A953D in the presence of ATP8B1/CDC50. 3H-PC extracted in the presence of 2mM 
TC was calculated as the percentage of total cellular radioactivity after subtraction of the background level 
from cells expressing the Walker B mutant ABCB4E558Q. The data were analysed by Student’s t-test (n ≥ 
3; *P < 0.01, ***P < 0.005). Inset shows percentage mean PC floppase activity after correction for ABCB4 
variant mean expression levels.  
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Figure 4. Effects of Potential Modulators of ABCB4 expression and function  
(A) Cells were triple-transfected to express wild-type ABCB4 (WT), ABCB4S320F or ABCB4A953D. Treatment 
with the proteasome inhibitor MG132 (10µM) 24h post-transfection induced accumulation of a smaller 
molecular weight form of the floppase, detected by western analysis. (B) Whole-cell lysates treated with 
PNGase F shows that deglycosylated mature protein migrates with the same mobility as the smaller 
molecular weight form produced by treatment with MG132 (loading was adjusted to ensure similar levels of 
variant and wild-type protein). (C) Representative gels and bar graph showing that treatment of triple 
transfected cells with CsA 24h post-transfection reproducibly causes the mature wild-type ABCB4 and 
ABCB4S320F to accumulate, but has no effect on the abundance of ABCB4A953D. Expression levels of the 
mature protein are normalised against β-tubulin expression. (D) CsA inhibits the PC floppase activity of wild-
type ABCB4. Triple-transfected cells were incubated with 0-1µM CsA 24h post-transfection for the indicated 
times. The media was washed from the cells and replaced with fresh media containing TC. Data were 
analysed by Student’s t-test (n ≥ 3; *P < 0.01, ***P < 0.005). Black vertical line(s) on panels B and C 







119x98mm (300 x 300 DPI)  
 
 







119x98mm (300 x 300 DPI)  
 
 






Figure 5. Effect of MG132 and CsA on ABCB4 Expression and Trafficking  
(A) Wild-type ABCB4. (B) ABCB4S320F. (C) ABCB4A953D. Cells were cultured on glass coverslips, triple-
transfected and treated 24h post-transfection with the proteasome inhibitor MG132 (10µM) or the chemical 
chaperone CsA (1µM) as indicated. The cells were fixed, stained and imaged by confocal microscopy 48h 
post-transfection. Staining as per Figure 2. Scale bar, 20µm.  
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S1 – Efficiency of plasmid uptake for triple transfection 
In order to quantify how many cells take up one, two or all three plasmids in our 
triple transfection protocol, cells were transfected with plasmids encoding the 
human scavenger receptor CD36 and the human multidrug resistance pump 
ABCB1 (both of which can be detected by monoclonal antibodies that recognize 
extracellular epitopes) and free cyan fluorescent protein (CFP).  Live cells were 
gated according to side and forward scatter reflecting normal cell size and 
granularity, respectively (left hand panel), then for recombinant protein 
expression. In the example shown, ABCB1 and CFP expression are detected in 
the middle panel. Double positive cells were then gated and assessed for 
expression of the third recombinant protein. In the example shown, the ABCB1 
and CFP positive cells were gated and assessed for expression of CD36 (right 
hand panel). The data show that 60% of the cells in the population were 
transfected and expressed both ABCB1 and CFP. Of these 96% also expressed 
CD36. We conclude therefore that if a cell is competent to take up one plasmid, it 
will take up all three. 
 
Materials and Methods: 
HEK293T ells were triple transfected using the PEI transfection reagent, as 
described in the main materials and methods. Forty-eight hours post 
transfection the cells were harvested, washed in FACS buffer (PBS and 1% fatty 
acid-free BSA) and resuspended at 1x107cells per ml. A saturating concentration 
(2μg) of mouse anti-CD36 monoclonal antibody mAb1258 was added to 50μl of 
cells and incubated for 30 minutes on ice. The cells were centrifuged at 400g for 
1 minute at 4°C and resuspended in 1ml FACS buffer. The wash step was 
repeated twice more and the cells resuspended in 50μl of FACS buffer. A 
saturating concentration (4μg) of goat, anti-mouse IgG secondary antibody 
conjugated to Alexafluor 647 (Invitrogen) was added to the cells and incubated 
in the dark for 30 mins on ice. The cells were recovered by centrifugation and 
washed as before, and then resuspended in 50μl FACS buffer.  To detect ABCB1, 
0.5µg PE-conjugated anti-ABCB1 monoclonal antibody UIC2 (Immunotech) was 
added to the cells and incubated in the dark, on ice, for 30 mins.  Cells were 
recovered and washed as above, then resuspended in 1ml FACS buffer. Flow 
cytometry was used to measure cellular fluorescence. 10,000 cells of normal size 
Page 30 of 30
Hepatology
Hepatology
and granularity were analyzed for CFP, CD36 and ABCB1 surface expression. The 
data was analysed by FlowJo (Treestar). 
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